ArticleThe Journal of cell biology1982
Taxol binds to cellular microtubules.
Article in The Journal of cell biology, 1982. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 409 citations in OpenAlex.
- Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.American journal of clinical oncology · 2014Trial
- [A randomized study on the effects of paclitaxel liposme and cisplatin induction chemotherapy followed concurrent chemoradiotherapy and sequential radiotherapy on locally advanced non-small cell lung cancer patients].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2011Trial
- Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.Investigational new drugs · 1998Trial
- Clinical pharmacokinetics of paclitaxel.Clinical pharmacokinetics · 1994Trial
- ILP4 and InR regulate paclitaxel-induced hypersensitivity differently inMolecular biology of the cell · 2026Article
- Recent advances in paclitaxel biosynthesis and regulation.Journal of experimental botany · 2025Review
- Microtubule regulation in cancer cells.Frontiers in cell and developmental biology · 2025Article
- Review
- Determinants of cytoplasmic microtubule depolymerization during ciliogenesis inLife science alliance · 2024Article
- Quantification of Engagement of Microtubules by Small Molecules in Living Cells by Flow Cytometry.ACS bio & med chem Au · 2022Article
- RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.BMC cancer · 2022Article
- The Mechanisms of Restenosis and Relevance to Next Generation Stent Design.Biomolecules · 2022Review
- Rationale for combination of paclitaxel and CDK4/6 inhibitor in ovarian cancer therapy - non-mitotic mechanisms of paclitaxel.Frontiers in oncology · 2022Review
- Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity.Journal of Cancer · 2022Review
- Paclitaxel-Based Chemotherapy Targeting Cancer Stem Cells from Mono- to Combination Therapy.Biomedicines · 2021Review
- Article
- Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel.Journal of cancer biology · 2021Article
- Nanomechanics in Monitoring the Effectiveness of Drugs Targeting the Cancer Cell Cytoskeleton.International journal of molecular sciences · 2020Review
- Synthesis and Biological Evaluation of New Antitubulin Agents Containing 2-(3',4',5'-trimethoxyanilino)-3,6-disubstituted-4,5,6,7-tetrahydrothieno[2,3-Molecules (Basel, Switzerland) · 2020Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Taxol is a low molecular weight plant derivative which enhances microtubule assembly in vitro and has the unique ability to promote the formation of discrete microtubule bundles in cells. Tritium-labeled taxol binds directly to microtubules in vitro with a stoichiometry approaching one (Parness, J., and S. B. Horwitz, 1981, J. Cell Biol. 91:479-487). We now report studies in cells on the binding of [3H]taxol and the formation of microtubule bundles. [3H]Taxol binds to the macrophagelike cell line, J774.2, in a specific and saturable manner. Scatchard analysis of the specific binding data demonstrates a single set of high affinity binding sites. Maximal binding occurs at drug concentrations which produce maximal growth inhibition. Conditions which depolymerize microtubules in intact and extracted cells as determined by tubulin immunofluorescence inhibit the binding of [3H]taxol. This strongly suggests that taxol binds specifically to cellular microtubules. Extraction with 0.1% Nonidet P-40 or depletion of cellular ATP by treatment with 10 mM NaN3 prevents the characteristic taxol-induced bundle formation. The binding of [3H]taxol, however, is retained under these conditions. Thus, there formation. The binding of [3H]taxol, however, is retained under these conditions. Thus, there must be specific cellular mechanisms which are required for bundle formation, in addition to the direct binding of taxol to cytoplasmic microtubules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.